The seladelpar-stoked selloff in CymaBay Therapeutics has engulfed fellow NASH player Genfit SA (GNFT -13.3%).
Seladelpar activates the peroxisome proliferator-activated receptor δ (PPARδ), expressed in a range of liver cells, which plays a key role in regulating genes involved in bile acid synthesis, inflammation, fibrosis and lipid metabolism.
Genfit’s lead drug is elafibranor, a PPAR alpha/delta agonist.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.